EXACT Sciences Corp (NASDAQ:EXAS)

CAPS Rating: 2 out of 5

An applied genomics company that develops proprietary DNA-based technologies for use in the detection of cancer.

Caps

How do you think EXAS will perform against the market?

Add Stock to CAPS Watchlist

All Players

243 Outperform
39 Underperform
 

All-Star Players

47 Outperform
15 Underperform
 

Wall Street

13 Outperform
1 Underperform
 

Top EXAS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

ELPastor (< 20)
Submitted October 27, 2014

Most people, it is safe to say, do not enjoy getting a colonoscopy. Therefore, any company that offers a non-invasive colorectal cancer screening test has a good chance of squeezing out a nice, large profit.

zzlangerhans (99.86)
Submitted June 26, 2016

Exact stock does well when something happens to fuel speculation about the long-term profitability of Cologuard, and badly when actual quarterly revenues and losses are released. That reminds me of another stock that has a large cult following and… More

EXAS VS S&P 500 (SPY)

Fools bullish on EXAS are also bullish on:

Fools bearish on EXAS are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about EXAS.

Recs

0
Member Avatar jclaypool (52.90) Submitted: 7/22/2018 2:21:34 PM : Outperform Start Price: $67.67 EXAS Score: +9.81

EXAS has a strong alternative product to a colonoscopy called Cologuard. With a proactive approach to getting patients to use the test kit EXAS is getting a higher compliance rate of users, which in turn makes the test more effective for physicians and insurers alike. While Cologuard is the growing revenue generator and could lead the company to profitability on its own, EXAS has shown a disciplined approach to investing in basic research. It is this ongoing pursuit that makes EXAS interesting as a potential growth stock.

Recs

0
Member Avatar TMFTypeoh (92.96) Submitted: 4/5/2018 7:25:21 AM : Outperform Start Price: $41.09 EXAS Score: +71.88

Man on man is this company expensive, but its got a huge opportunity ahead.

Recs

0
Member Avatar brandstudere (88.57) Submitted: 3/7/2018 6:25:35 AM : Outperform Start Price: $38.49 EXAS Score: +75.66

Unmet needs in CRC screening; helping to close the gap in screening rates.
Pipeline can provide significant tailwinds for years to come.

Leaderboard

Find the members with the highest scoring picks in EXAS.

Score Leader

proisback

proisback (57.27) Score: +2,186.56

The Score Leader is the player with the highest score across all their picks in EXAS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
proisback 57.27 9/24/2009 Outperform 3M $2.88 +2,332.68% +146.12% +2,186.56 1 Comment
theonlypro4U < 20 9/23/2009 Outperform 3M $2.89 +2,324.26% +143.45% +2,180.82 1 Comment
chas1232123 < 20 9/23/2009 Outperform 3Y $2.91 +2,307.68% +144.67% +2,163.01 1 Comment
coolyo514 84.25 12/17/2009 Outperform 5Y $2.94 +2,284.58% +136.97% +2,147.60 0 Comment
DUTCHMAN67 63.90 12/17/2009 2/16/2012 Outperform 5Y $2.96 +2,267.73% +137.44% +2,130.29 0 Comment
JavaChipFool 72.11 12/22/2009 Outperform 5Y $2.97 +2,258.88% +134.22% +2,124.67 1 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. pantastic 77.56 12/17/2009 Outperform 5Y $2.98 +2,251.13% +137.29% +2,113.83 0 Comment
NickJ100 78.85 12/17/2009 9/24/2014 Outperform 1Y $3.01 +2,227.61% +136.80% +2,090.82 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. jpmj 66.70 12/18/2009 11/23/2014 Outperform 5Y $3.05 +2,197.09% +138.66% +2,058.43 0 Comment
fiberoptical 57.05 12/18/2009 Outperform 3M $3.06 +2,189.58% +137.66% +2,051.92 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 85.13 5/3/2017 Outperform 3W $31.31 +123.77% +9.82% +113.95 0 Comment
trackcraighallum 54.22 6/16/2016 Outperform NS $9.92 +606.26% +26.69% +579.58 0 Comment
TrackJimCramer 85.13 7/22/2015 Underperform 3W $25.29 +23.80% +12.87% -10.94 5/3/2017 @ $31.31 0 Comment
TrackGoldmanSach 74.40 6/4/2014 Outperform NS $14.20 +393.39% +36.07% +357.32 0 Comment
TrackRothCapital 74.75 12/20/2012 Outperform NS $10.43 +571.73% +81.40% +490.33 0 Comment
TrackUltraLong < 20 2/6/2012 Underperform NS $9.57 +632.09% +94.94% -537.15 1 Comment
TrackCanaccord 68.73 1/6/2012 Outperform NS $8.41 +733.07% +104.29% +628.78 0 Comment
TrackJMP 84.71 1/5/2012 Outperform NS $8.12 +762.82% +106.64% +656.18 0 Comment
TrackRodmanRen < 20 8/15/2011 Outperform NS $6.74 +939.48% +119.73% +819.75 0 Comment
TrackWedbush 87.11 6/28/2011 Outperform NS $8.03 +772.49% +103.89% +668.60 0 Comment
TrackTheBenchmar 85.66 4/28/2011 Outperform NS $7.45 +840.42% +93.38% +747.03 0 Comment
TrackAurigaUSA 52.42 3/1/2011 Outperform NS $5.65 +1,140.02% +96.08% +1,043.94 0 Comment
TrackWMBlair 78.90 12/14/2010 Outperform NS $5.72 +1,124.85% +109.49% +1,015.36 0 Comment
TrackJimCramer 85.13 10/13/2010 Outperform 3W $8.39 +201.43% +79.18% +122.25 7/22/2015 @ $25.29 0 Comment
TrackJefferies 83.87 9/9/2010 Outperform NS $5.17 +1,255.15% +134.57% +1,120.58 0 Comment
TrackRWBaird 86.94 3/4/2010 Outperform NS $4.25 +1,548.50% +132.90% +1,415.60 0 Comment
TrackRodmanRen < 20 2/2/2010 Outperform NS $4.25 +80.24% +14.87% +65.37 8/3/2011 @ $7.66 0 Comment

Advertisement